Mobile website
Expert Forum
Current situation and prospect of biotherapy of metastatic renal cell carcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Due to the inherent resistance,renal cell carcinoma (RCC) is insensitive to radiotherapy and chemotherapy;thus, biotherapy is the only option for patients with metastatic renal cell carcinoma (mRCC). With the further understanding of RCC, small molecule targeted drug therapy has gradually replaced the previous cytokine therapy. In recent years, new immunotherapy has become the focus of research in the biotherapy of RCC. Small molecule targeted drug therapy and new immunotherapy have shown great advantages in the treatment, they can improve the survival time and quality of life for RCC patients; however,the low response rate, drug-esistance, side effects and other issues also appear. Thus, providing personalized treatment to bring greater benefits for RCC patients is the goal for clinical practitioners.
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation of China（No.281730073），and theTranslation and Application of Precise Medicine of Second Military Medical Unversity（No. 2017JZ22）
Clc Number:
